Pleasanton, July 24, 2025 (GLOBE NEWSWIRE) -- Boster Bio pioneers free antibody validation, revolutionizing IHC services with guaranteed reagent reliability, setting new standards for reproducible ...
Boster Biological Technology (Boster Bio), a supplier of high-quality antibodies and immunoassays for over 30 years and a recipient of CiteAb recognition for antibody quality, announced a free ...
BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing cancer diagnostic tissue testing with the first immunohistochemistry (IHC) laboratory reference standards, today announced it ...
Boston Cell Standards enters into final phase of US FDA’s MDDT programme to qualify first-in-industry to standardize cancer diagnostic assays: Boston Wednesday, April 29, 2026, ...
Immune phenotype profiling based on anatomic origin of melanoma and impact on clinical outcomes of immune checkpoint inhibitor treatment. Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: ...
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers We optimized and validated immunohistochemistry assays in breast ...
The Canary Foundation Retrospective Prostate Tissue Microarray Resource has been described in detail elsewhere. 27 Briefly, it is a multicenter, retrospective prostate cancer tissue microarray created ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results